The European Journal of Hospital Pharmacy: Science and Practice

The European Association of Hospital Pharmacists (EAHP) announces a new partnership with the BMJ Group to publish the peer review journal European Journal of Hospital Pharmacy: Science and Practice (EJHP), launching in January 2012.

The existing journals EJHP Science and EJHP Practice will be combined to make the new journal.

Learn more about this exciting development from the EAHP President and Editor in Chief.

Benefits provided by the new journal include:

· Knowledge – the journal will concentrate on scientific content which will help you in your daily practice and professional content which will develop your career

· In-depth – coverage of all aspects of hospital pharmacy including clinical, therapeutic, economic and social disciplines giving you the full picture

· Ease – all the information that you require will be in one easy to read journal saving you time

EJHP will become more and more an educational tool answering the emerging questions of the pharmacy profession and will also continue to give updated information on professional and political developments.

Find out what the EAHP President’s views are on this new exciting development.

To submit a new paper, become a reviewer or for further information, please visit ejhp.bmj.com.

Please note: authors who have submitted papers after 1st September 2011 to EJHP Science or EJHP Practice will need to re-submit to EJHP: Science and Practice using the new Instructions for Authors.

Sources

http://www.eahp.eu/

http://journals.bmj.com/site/marketing/ejhp/index.xhtml

Strategy to Better Protect Public Health by Strengthening and Rationalising EU Pharmacovigilance

Public consultation on a concept paper on implementing measures for the performance of pharmacovigilance activities
 
In order to harmonise the performance of the new pharmacovigilance activities introduced by the amended pharmacovigilance legislation (cf. Regulation (EU) No 1235/2010 and Directive 2010/84/EU) the Commission shall adopt several implementing measures. Those measures supplement essential details of the new pharmacovigilance system with the more technical details that have to be observed by marketing authorisation holders, national competent authorities and the European Medicines Agency in the daily practice of applying the new provisions.

With the public consultation the European Commission intends to describe the scope and content of the implementing measure which it is currently considering and seeks views and feedback from stakeholders on those issues. A more detailed description can be found in the concept paper [109 KB] .

The period of consultation ends on 7 November 2011. All citizens and organisations (public and private) are welcome to contribute to this consultation. For more information on how to contribute, please read the concept paper.

Received contributions will be published on the internet. For more information on the processing of personal data in the context of this consultation, read the specific Privacy Statement [16 KB] .

Sources

Public Health

Pharmanews